Courtney Marabella

Articles

Niraparib Demonstrates PFS Benefit in Chinese Population With Advanced Ovarian Cancer

December 01, 2021

First-line maintenance treatment with the PARP inhibitor niraparib yielded a clinically meaningful and statistically significant improvement in progression-free survival vs placebo in Chinese patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status, according to data from the phase 3 PRIME trial.

Sacituzumab govitecan-hziy improves quality of life in patients with metastatic triple-negative breast cancer

October 06, 2021

Sacituzumab govitecan-hziy resulted in a statistically significant and clinically meaningful improvement in health-related quality of life compared with single-agent chemotherapy of physician’s choice in patients with metastatic triple-negative breast cancer.